Good Outcomes Following Reverse Switching From CT-P13 to Originator Infliximab in IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
Inflamm. Bowel Dis. 2021 Feb 04;[EPub Ahead of Print], S Mahmmod, JPD Schultheiss, AA van Bodegraven, G Dijkstra, LPL Gilissen, F Hoentjen, MWMD Lutgens, N Mahmmod, AE van der Meulen-de Jong, LJT Smits, ACITL Tan, B Oldenburg, HH FidderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.